Photo of John M. Pagel

John M. Pagel, M.D., Ph.D.


Professional Statement

Dr. Pagel is an international hematology expert with a world-class reputation for research and excellence in patient care. He is dedicated to individualized patient care that is based on mutual respect and trust. He is incredibly excited to be a part of the Swedish Cancer Institute. Dr. Pagel feels the work being done here is life-changing for patients and will deliver new advancements in cancer treatment for patients in the Pacific Northwest and beyond. Prior to joining Swedish, Dr. Pagel spent more than a decade as an associate member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center and associate professor in the Medical Oncology Division at the University of Washington. In his spare time Dr. Pagel enjoys skiing, boating, hiking and running in the Pacific Northwest.

Read More

Accepts 46 Insurance Plans

Please contact the practice directly to confirm your health plan is accepted
  • Aetna Medicare Advantage HMO
  • Aetna Medicare Advantage PPO
  • Aetna PPO/POS
  • Aetna Whole Health - Polyclinic
  • Aetna Whole Health - Providence Swedish
  • Aetna Whole Health - Puget Sound
  • Amerigroup Amerivantage Dual Coordination
  • Amerigroup Amerivantage HMO
  • Amerigroup Medicaid (Apple Health/Healthy Options/CHIP)
  • Bluecross/Blueshield Bluecard PPO
  • CHPW Medicaid (Apple Health/Healthy Options/CHIP)
  • Cigna Behavioral Health
  • Cigna/Greatwest Healthcare PPO
  • Coordinated Care Ambetter Exchange HMO
  • Coordinated Care Medicaid (Apple Health/Healthy Options/CHIP)
  • Coventry/First Health PPO
  • First Choice PPO
  • Humana Medicare Advantage
  • Humana PPO
  • Kaiser (Contract Limitations)
  • LifeWise Connect Exchange
  • LifeWise PPO
  • Medicaid of Washington
  • Medicare
  • Molina Marketplace Exchange HMO
  • Molina Medicaid (Apple Health/Healthy Options/CHIP)
  • Molina Medicare Advantage
  • Multiplan PPO
  • Optum/Optum Behavioral Health
  • PacMed USFHP
  • Premera Heritage
  • Premera Heritage Signature
  • Premera Medicare Advantage HMO
  • Private Healthcare Systems (PHCS) PPO
  • Providence Health Plan Medicare Advantage
  • Regence MedAdvantage PPO
  • Regence PPO
  • Triwest VAPC3/Choice Card
  • United Behavioral Health Medicaid
  • United Behavioral Health Medicare Advantage
  • United Behavioral Health PPO
  • United HealthCare AARP HMO
  • United HealthCare Medicare Advantage
  • United HealthCare PPO
  • Workers' Compensation (L&I)
Read More


Boston University School of Medicine
medical school, 1996
University of California, San Francisco
residency, Internal Medicine, Oncology, 1999
University of Washington/Fred Hutchinson Cancer Research Center, Senior Fellow, Dept. of Medicine, Division of Oncology
fellowship, Medical Oncology, 2002

Board Certifications

American Board of Internal Medicine
Medical Oncology

Clinical Interests

  • Blood Cancer
  • Cancer Chemotherapy
  • Hematologic Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myelodysplasia
  • Myelodysplastic Syndrome
Read More

Personal Interests

Skiing, boating, running, hiking
Read More


  • Mawad R, Lionberger J, Sandhu R, Gooley TA, Shannon-Dorcy K, Dean C, Scott B, Sandmaier BM, O’Donnell P, Becker P, Petersdorf S, Hendrie P, Sorror ML, Holm N, Deeg J, Appelbaum FR, Estey EH., Pagel JM. Frequency of Allogeneic Hematopoietic Cell Transplantation among High-or Intermediate-Risk AML Patients in First Complete Remission. J Clin Oncol. In Press.
  • Ostronoff F, Othus M, Kantari H, Meshinshi S, Ravindi F, Hendrie PC, Faderl S, Becker PS, Cortes J, Pagel JM, Peters S, Godwin J, Willman C, Pierce S, List A, Sandhu V, Walter RB, Stirewalt DL, Appelbaum F, Chiatovich TJ, Esety EH. A Model for Prediction of FLT3-ITD and NPM1 (without FLT3-ITD) Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. Br J Haematol. In Press.
  • Orozco JJ, Back T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 Radioimmunotherapy Using 211At with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model. Blood. 121(18):3759-3767, 2013.
  • Cairo MS, Woessmann W, Pagel JM. Advances in Hematopoietic Stem Cell Transplantation (HSCT) in Childhood and Adolescent Lymphomas. Biol Blood Marrow Transplant. 19(1 Suppl):S38-S43, 2013.
  • Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE, Frayo SL, Warr TA, Boyd TE, Press OW, Gopal AK. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol. 161(2):183-191, 2013.
  • Timmerman JM, Byrd JC, Andorsky DJ, Yamada R, Kramer J, Muthusamy N, Hunder N, Pagel JM. A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. Clinical Cancer Research. 18(20):5752-5760, 2012.
  • Hattori N, Gopal AK, Shields AT, Fisher DR, Gooley T, Pagel JM, Press OW, Rajendran JG. 131I-Tositmomab Myeloablative Radioimmunotherapy for Non-Hodgkin Lymphoma: Radiation Dose to Testes. Nuclear Medicine Communications. 33(12):1225-1231, 2012.
  • Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP, Sandmaier BM, Sorror M, Stirewalt DL, Wilson WA, Storb R, Appelbaum FR, Gooley T. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 120(7):1398-1408, 2012.
  • Karp JE, Garrett-Mayer EL, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showell MM, Othus M, Doyle LA, Wright JJ, Pagel JM. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 97(11):1736-1742, 2012.
  • Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 119(17):3940-3950, 2012.
  • Park SI, Shenoi J, Frayo SL, Hamlin DK, Lin Y, Wilbur DS, Stayton PS, Orgun NN, Hylarides MD, Buchegger F, Kenoyer AL, Axtman A, Gopal AK, Green DJ, Pagel JM, Press OW. Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma. Clin Cancer Res.17(23):7373-7382, 2011.
  • O’Donnell PV, Harrington E, Gooley TA, Pagel JM, Pereira S, Flowers ME, Hansen JA, Burroughs LM, Sandmaier BM, Storb RF, Luznik L, Jones RJ, Symonds HJ, Kasamon YL, Fuchs E. Cyclophosphamide-Induced Tolerance Following Bone Marrow Transplantation from Haploidentical Donors. Haematologica (Extra 1)
  • Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH. Clofarabine with High Dose Cytarabine Granulocyte Colony-Stimulating Factor (G-CSF) Priming for Relapsed and Refractory Acute Myeloid Leukemia. Br J Haematol. 155(2):182-189, 2011.
  • Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger W, Holmberg LA, Shustov AR, Maloney DG, Gopal AK. Mantle Cell International Prognostic Index but not Pretransplantation Induction Regimen Predicts Survival for Patients with Mantle-Cell Lymphoma receiving High Dose Therapy and Autologous Stem-Cell Transplantation. J Clin Oncol. 29(22):3023-3029, 2011.
  • Pagel JM, Kenoyer AL, Back T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozoco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Anti-CD45 Pretargeted Radioimmunotherapy using Bismuth-213: High Rates of Complete Remission and Long-Term Survival in a Mouse Myeloid Leukemia Xenograft Model. Blood. 118(3):703-711, 2011.
  • Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, Matesan MC, Storb RF, Press OW. 90Y-ibritumomab Tiuxetan, Fludarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for Patients with Persistent High-Risk B-Cell Lymphoma. Blood. 118(4):1132-1139, 2011.
  • Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers MED, O’Donnell P, Sandmaier BM, Storb RF, Gopal AK. Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant.17(10):1537-1545, 2011.
  • Walter RB, Gooley T, Loken M, Estey E, Becker PS, Salter AI, Lansverk E, Appelbaum FR, Pagel JM. Impact of Pre-Transplant Minimal Residual Disease on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia in First Complete Remission. J Clin Oncol. 29(9):1190-1197, 2011.
  • Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP, Sandmaier BM, Warren EH, Storb RF, Appelbaum FR, Deeg HJ. Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival is Determined by Karyotype and Comorbidities. Biol Blood Marrow Transplant. 17(6):908-915, 2011.
  • Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Back T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and Pretargeted Radioimmunotherapy Using Bismuth-213 to Target and Treat Non-Hodgkin Lymphomas Expressing CD20: A Preclinical Model for Optimal Consolidation Therapy to Eradicate Minimal Residual Disease. Blood. 116(20):4231-4239, 2010.
  • Wilbur DS, Park SI, Chyan MK, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur S, Buchegger F, Pantelias A, Pagel JM, Press OW. Design and Synthesis of Bis-Biotin-Containing Reagents for Application to Monoclonal Antibody-Based Pretargeting Using Streptavidin Mutants. Bioconjug Chem. 21(7):1225-1238, 2010.
  • Green DJ, Pagel JM, Nemecek ER, Lin Y, Kenoyer A, Pantelias A, Wilbur DS, Hamlin DK, Gopal AK, Park SI, Press OW. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in non-human primates. Blood. 114(6):1226-1235, 2009.
  • Gopal AK, Pagel JM, Fromm JR, Wilbur S, Press OW. I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin Lymphoma. Blood. 113(23):5905-5910, 2009.
  • Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM. Biodistributions, Myelosuppression and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211. Cancer Res. 69(6):2408-2415, 2009.
  • Pagel JM, Orgun N, Hamlin DK, Wilbur S, Gooley T, Gopal AK, Park SI, Green D, Lin Y, Press OW. A Comparative Analysis of Conventional and Pretargeted Radioimmunotherapy of B-Cell Lymphomas by Targeting CD20, CD22, and HLA-DR Singly and in Combinations. Blood. 113(20):4903-4913, 2009.
  • Pagel JM, Matthews DC, Kenoyer A, Hamlin D, Wilbur DS, Fisher D, Gopal AK, Lin Y , Saganic L, Appelbaum FR, Press OW. Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia. Cancer Res. 69(1):185-192, 2009.
  • Gopal AK, Metcalfe TL, Gooley TA, Press OW, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Maloney DG. High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer. 113(6):1344-1350, 2008.
  • Till BG, Jensen MC, Wang J, Chen EY, Wood BL, James S, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW. Adoptive Immunotherapy for Non-Hodgkin Lymphoma Using Genetically Modified Autologous CD20-Specific T Cells. Blood. 112(6):2261-2271, 2008.
  • Gopal AK, Press OW, Wilbur DS, Maloney D, Pagel JM. Rituximab blocks binding of radio-labeled anti-CD20 antibodies (Ab) but not radio-labeled anti-CD45-Ab. Blood. 112(3):830-835, 2008.
  • Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur DS, Nilsson R, Sandberg B, Press OW. Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies. Cancer Biother Radiopharm. 23(2):181-191, 2008.
  • Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger W, Press OW. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma. 29:1-12, 2008.
  • Walter RB, Boyle KM, Appelbaum FR, Bernstein ID, Pagel JM. Simultaneously Targeting CD45 Significantly Increases Cytotoxicity of the Anti-CD33 Immunoconjugate, Gemtuzumab Ozogamicin, Against Acute Myeloid Leukemia (AML) Cells and Improves Survival of Mice Bearing Human AML Xenografts. Blood. 111(9):4813-4816, 2008.
  • Pagel JM, Hedin N, Drouet L, Wood B, Pantelias A, Lin Y, Hamlin DK, Wilbur DS, Gopal AK, Green D, Appelbaum FR, Press OW. Eradication of Disseminated Leukemia in a Syngeneic Murine Leukemia Model Using Pretargeted Anti-CD45 Radioimmunotherapy. Blood. 111(4):2261-2268, 2008.
  • Pham RN, Gooley TA, Keeney GE, Press OW, Pagel JM, Greisman HA, Bensinger WI, Holmberg LA, Petersdorf SH, Maloney DG Gopal AK. The Impact of Histologic Grade on the Outcome of High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma. Bone Marrow Transplant. 40(11):1039-1044, 2007.
  • Keeney GE, Gooley TA, Press OW, Pagel JM, Petersdorf SH, Maloney DG, Gopal AK. The Pretransplant Follicular Lymphoma International Prognostic Index is Associated with Survival of Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Leuk Lymphoma. 48(10):1961-1967, 2007.
  • Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal A, Hamlin DK, Press OW. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res. 13(18):5598s-5603s, 2007.
  • Pagel JM, Lionberger J, Gopal AK, Sabath DE, Loeb K. Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Am J Hematol. 82(12):1121-1122, 2007.
  • Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW. Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-cell Lymphomas. Cancer Res. 67(12):5921-5298, 2007.
  • Ying SX, Seal S, Abbassi N, Kiem HP, Pagel JM, Gopal AK, Deeg J. Differential Effects of Bexarotene on Intrinsic and Extrinsic Pathways in TRAIL-Induced Apoptosis in Myeloid Leukemia Cell Lines. Leuk Lymphoma. 48(5):1003-1014, 2007.
  • Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF Appelbaum FR, Press OW. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 25(11):1396-1402, 2007.
  • *Pantelias A, *Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Stone D, Axworthy D, Gopal AK, Press OW. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22 and DR molecules on human B cell lymphomas. Blood. 109(11):4980-4987, 2007. *Shared first author
  • Gopal AK, Pagel JM, Rajendran JG, Maloney DG, Appelbaum FR, Sorror ML, Sandmaier BM, Storb R, Press OW. Improving the Efficacy of Reduced-Intensity Allogeneic Transplantation for Lymphoma Using Radioimmunotherapy. Biol. Blood Marrow Transplant. 12(7):697-702, 2006.
  • *Lin Y, *Pagel JM, Axworthy D, Hedin N, Press OW. A Genetically Engineered scFv4SA Fusion Protein for Pretargeted Radioimmunotherapy. Cancer Res. 66(7):3884-3892, 2006. *Shared first author
  • Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur DS, Press OW. Comparison of a Tetravalent Single-Chain Antibody-Streptavidin Fusion Protein and an Antibody-Streptavidin Chemical Conjugate for Pretargeted Anti-CD20 Radioimmunotherapy of B-cell Lymphomas. Blood. 108(1):328-336, 2006.
  • Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek ER, Sickle E, Durack L, Carreras J, Horowitz MM, Press OW, Gopal AK, Martin PJ, Bernstein ID, Matthews DC. 131I-anti-CD45 Antibody Plus Busulfan and Cyclophosphamide before Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia in First Remission. Blood. 107(5):2184-2191, 2006.
  • Kerbauy DMB, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, Myerson D, Appelbaum FR, Storb R, Deeg HJ. Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Biol. Blood Marrow Transplant. 11(9):713-720, 2005
  • Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF, Darden DE, Nolan CE, Gressick LA, Yang J, Chyla BJ, Busman TA, Graham AM, Cerri E, Enschede SH, Humerickhouse RA, Seymour JF. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-to
  • Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Deeg J, Shields A, Green DJ, Maloney DG, Sandmaier BM, Storb R, Appelbaum FR, Press OW, and Pagel JM. A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Journal of the Am Soc of Hematology, poster presentation, 2012.
  • .Mawad R, O’Donnell P, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Deeg HJ, Shields A, Green DJ, Maloney DG, Sandmaier BM, Storb R, Appelbaum FR, Press OW, and Pagel JM. Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT. Journal of the Am Soc of Hematology, poster presentation, 2012.
  • Mawad R, Gooley TA, Rajendran JG, Fisher DR, Shield A, Orozco JJ, Hamlin DK, Wilbur DS, Hylarides MD, Gopal AK, Green DJ, Maloney DG, Sandmaier BM, Storb R, Appelbaum FR, Press OW, and Pagel JM. Pretargeted Radioimmunotherapy using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation. American Society of Blood and Marrow Transplantation, oral presentation, 2013.
  • Orozco JJ, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Mawad R, Frayo SL, Hylarides MD, Green DJ, Gopal AK, O’Donnell P, Sandmaier BM, Press OW, and Pagel JM. Anti-CD45 Pretargeted Radioimmunotherapy Prior to Bone Marrow Transplantation without Total Body Irradiation Facilitates Engraftment from Haploidentical Donors and Prolongs Survival in a Disseminated Murine Leukemia Model. American Society of Blood and Marrow Transplantation, Poster presentation, 2013.
  • Lionberger JM, Dean C, Wathen K, Scott B, Estey EH, Pagel JM. Innovative Phase I/II Statistical Design in Combination Chemotherapy that Combines Toxicity and Efficacy Parameters to Increase Study Efficiency: Bendamustine and Idarubicin in de novo Adult AML. In preparation.
  • Newell L, Sandhu R, Becker P, Pagel JM, Hendrie P, Walter R, Petersdorf S, Shannon Dorcy K, Abkowitz J, Appelbaum F, Estey E. Probability of Eventual CR after Course 1 of Induction Therapy for Newly-Diagnosed AML as a Function of Speed of Neutrophil and Platelet Recovery. In preparation.
  • Pagel JM, Spurgeon S, Awan F, Blum K, Lanasa MC, Flinn IW, Stromatt SC, Byrd JC, Gopal A. Phase 1 Study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and/or refractory NHL patients. In preparation.
  • Orozco JJ, Kenoyer A, Hamlin DK, Wilbur DS, Fisher DR, Hylarides MD, Axtman A, Frayo SL, Green DJ, Gopal AK, O’Donnell P, Press OW, Pagel JM. Haploidentical Bone Marrow Transplantation using Anti-CD45 Radioimmunotherapy to Decrease Relapse in a Pre-clinical Murine Model. In preparation.
  • Sandhu R, Lionberger JM, Othus M, Pagel JM, Shannon-Dorcy K, Hendrie P, Petersdorf S, Becker P, Appelbaum F, Estey EH.. Survival after Failure of Initial Therapy for Newly-Diagnosed or Relapsed/ Refractory AML at an Academic Center: Subsequent Clinical Trial vs. Not. Submitted.
  • Estey E, Veatch JR, Sandhu V, Becker PS, Pagel JM, Appelbaum F. Relation between the NCI common toxicity criteria and treatment related mortality in acute myeloid leukemia (AML). Submitted.
  • Cassady RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK. Specific features identify patients with relapsed/refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Submitted.
  • Grosschedl R, Giese K, Pagel J. HMG Domain Proteins: Architectural Elements in the Assembly of Nucleoprotein Structures. Trends in Genetics 10:94-100, 1994.
  • Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. The Use of Radioimmunoconjugates in Stem Cell Transplantation. Bone Marrow Transplantation 29(10):807, 2002.
  • Pagel JM. Radioimmunotherapeutic approaches for leukemia: the past, present and future. Cytotherapy 10(1):13-20, 2008.
  • Pagel JM, Boerman O, Breitz HB, Meredith R. “Targeted Radionuclide Therapy of Cancer”. Chapter 13 in the 5th Edition of Principles of Cancer Biotherapy, Oldham RK, Dillman RO, (eds.) Published August 2009.
  • Shenoi J, Gopal AK, Press OW, Pagel JM. Novel Radioimmunotherapeutic Approaches for Allogeneic Hematopoietic Cell Transplantation - Current Trends to Reduce Relapse. Invited Review. Current Opinion in Oncology 22(2):143-149, 2010.
  • Walter RB, Press OW, Pagel JM. Pretargeted Radioimmunotherapy for Hematologic and Other Malignancies. Cancer Biotherapy & Radiopharmaceuticals 25(2): 125-142, 2012.
  • Walter RB, Pagel JM. Targeted Radionuclide Therapy for Leukemia (chapter 34). In: Speed TW (Ed). Targeted Radionuclide Therapy. 1st edition. Lippincott Williams & Wilkins. 2011; pp. 411-457.
  • Gutman JA, Smith KM, Pagel JM. Chronic Lymphocytic Leukemia (CLL) (chapter 3). In: Estey EH & Appelbaum FR (Eds). Leukemia and Related Disorders: Integrated Treatment Approaches. Humana Press. 2012; pp. 67-96. Invited Book Chapter.
  • Orozco J, Zeller J, Pagel JM. Radioactive Isotopes Combined with Antibodies Directed at CD45 for Conditioning Prior to Allogeneic Transplant in AML. Therapeutic Advances in Hematology, Invited Review. Therapeutic Advances in Hematology 3(1):5-16, 2012.
  • Mawad R, Lionberger JM, Pagel JM. Strategies to Reduce Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Current Hematologic Malignancy Reports 8(2):132-140, 2013.
  • Pagel JM, Gopal AK. Radioimmunotherapy and Hematopoietic Cell Transplantation. In: Appelbaum FR, Negrin R, Antin J, and Forman SJ (Eds). Hematopoietic Cell Transplantation. 5th edition. Blackwell Scientific. Invited Book Chapter. In Press.
  • Pagel JM, Hatfield GW. Integration Host Factor-mediated Expression of the ilvGMEDA Operon of Escherichia coli. J Biol Chem. 266:1985-1996, 1991.
  • Pagel JM, Winkelman JW, Adams CA, Hatfield GW. DNA topology-mediated regulation of transcription initiation from the tandem promoters of the ilvGMEDA operon of Escherichia coli. J Mol Biol. 224:919-935, 1992.
  • Giese K, Pagel J, Grosschedl R. Distinct DNA-binding Properties of the High Mobility Group Domain of Murine and Human SRY Sex-Determining Factors. Proc Natl Acad Sci USA. 91:3368-3372, 1994.
  • Giese K, Pagel J, Grosschedl R. Functional Analysis of DNA Bending and Unwinding by the High Mobility Group Domain of LEF-1. Proc Natl Acad Sci USA. 94(24):12845-12850, 1997.
  • Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallet RW, Stayton PS, Press, OW. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med. 44:437-445, 2003.
  • Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Wilbur DS, Matthews DC, Press, OW. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 101(8):2340-2348, 2003.
  • Pagel JM, Kerr KM, Kirkwood KS, Welton M, Abbo M, Hricak H, Pantilat SZ. Retrospective Analysis of a Guideline for the Evaluation of Older Patients with Non-Traumatic Abdominal Pain Presenting to the Emergency Department. J Clin Outcomes Manage. 10(11):1-7, 2003.
  • *Gopal AK, *Pagel JM, Hedin N, Press OW. Fenretinide Enhances Rituximab-Induced Cytotoxicity against B Cell Lymphoma Xenografts through a Caspase-Dependent Mechanism. Blood. 103(9):3516-3520, 2004. *Shared first author
  • Nemecek ER, Hamlin DK, Fisher DR, Krohn KA, Pagel JM, Appelbaum FR, Press OW, Matthews DC. Biodistribution of 90Y-labeled anti-CD45 antibody in a nonhuman primate model. Clin Cancer Res 11:787-794, 2005.
  • Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR, Storb R, Gopal AK. Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older. J Clin Oncol. 23(15):3439-3446, 2005.
  • Pagel JM, Laugen C, Hedin N, deVries P, Coon M, Bonham L, Singer J, Press OW. I Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res. 11(13):4857-4866, 2005.
  • Kerbauy DMB, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, Myerson D, Appelbaum FR, Storb R, Deeg HJ. Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Biol. Blood Marrow Transplant. 11(9):713-720, 2005.
Read More

Professional Associations

Am. Society of Clinical Oncology, Am. Society for Blood and Marrow Transplantation, Am. Society of Hematology, Am. Assoc. for Cancer Research, Institute of Translational Health Sciences, Puget Sound Oncology Consortium
Read More


  • English

Practice Locations

John M. Pagel practices at one location

Affiliated Facilities
  • Swedish Cherry Hill
  • Swedish Edmonds
  • Swedish First Hill
Medical Groups
Swedish Medical Group logo